Relevant bibliographies by topics / SGLT 2 Inhibitors

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'SGLT 2 Inhibitors'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'SGLT 2 Inhibitors.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "SGLT 2 Inhibitors"

1

Sipos, Ádám, Eszter Szennyes, Nikolett Éva Hajnal, et al. "Dual-Target Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) Inhibitors." Pharmaceuticals 14, no. 4 (2021): 364. http://dx.doi.org/10.3390/ph14040364.

Full text
Abstract:
A current trend in the quest for new therapies for complex, multifactorial diseases, such as diabetes mellitus (DM), is to find dual or even multi-target inhibitors. In DM, the sodium dependent glucose cotransporter 2 (SGLT2) in the kidneys and the glycogen phosphorylase (GP) in the liver are validated targets. Several (β-D-glucopyranosylaryl)methyl (het)arene type compounds, called gliflozins, are marketed drugs that target SGLT2. For GP, low nanomolar glucose analogue inhibitors exist. The purpose of this study was to identify dual acting compounds which inhibit both SGLTs and GP. To this en
APA, Harvard, Vancouver, ISO, and other styles
2

Madunić, Ivana Vrhovac, Josip Madunić, Davorka Breljak, Dean Karaica, and Ivan Sabolić. "Sodium-glucose cotransporters: new targets of cancer therapy?" Archives of Industrial Hygiene and Toxicology 69, no. 4 (2018): 278–85. http://dx.doi.org/10.2478/aiht-2018-69-3204.

Full text
Abstract:
AbstractGlucose, the key source of metabolic energy, is imported into cells by two categories of transporters: 1) facilitative glucose transporters (GLUTs) and 2) secondary active sodium-glucose cotransporters (SGLTs). Cancer cells have an increased demand for glucose uptake and utilisation compared to normal cells. Previous studies have demonstrated the overexpression of GLUTs, mainly GLUT1, in many cancer types. As the current standard positron emission tomography (PET) tracer 2-deoxy-2-(18F)fluoro-D-glucose (2-FDG) for imaging tumour cells via GLUT1 lacks in sensitivity and specificity, it
APA, Harvard, Vancouver, ISO, and other styles
3

Nagata, Takumi, Masanori Fukazawa, Kiyofumi Honda, et al. "Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats." American Journal of Physiology-Endocrinology and Metabolism 304, no. 4 (2013): E414—E423. http://dx.doi.org/10.1152/ajpendo.00545.2012.

Full text
Abstract:
To understand the risk of hypoglycemia associated with urinary glucose excretion (UGE) induced by sodium-glucose cotransporter (SGLT) inhibitors, it is necessary to know the relationship between the ratio of contribution of SGLT2 vs. SGLT1 to renal glucose reabsorption (RGR) and the glycemic levels in vivo. To examine the contributions of SGLT2 and SGLT1 in normal rats, we compared the RGR inhibition by tofogliflozin, a highly specific SGLT2 inhibitor, and phlorizin, an SGLT1 and SGLT2 (SGLT1/2) inhibitor, at plasma concentrations sufficient to completely inhibit rat SGLT2 (rSGLT2) while inhib
APA, Harvard, Vancouver, ISO, and other styles
4

Nasir Khan, Amir Khan, Shagufta Naseer, et al. "Prospective Evaluation of Atrial Fibrillation Risk in Type 2 Diabetes Comparing SGLT-2 Inhibitors and DPP-4 Inhibitors." Indus Journal of Bioscience Research 3, no. 3 (2025): 69–75. https://doi.org/10.70749/ijbr.v3i3.797.

Full text
Abstract:
Background: Type 2 diabetes mellitus (T2DM) is a major risk factor of atrial fibrillation (AF). In particular, sodium glucose co-transporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors are often used to treat T2DM, and effects of these drugs on risk for AF are unknown. The goal of this study was to investigate if SGLT 2 inhibitor are associated with an increase in the incidence of new onset AF, as well as the incidence of cardiovascular outcomes, versus DPP4 inhibitors. Prospective cohort study was conducted at Lady Reading Hospital, Peshawar from July 2024 to December 20
APA, Harvard, Vancouver, ISO, and other styles
5

Basak, Debasish, David Gamez, and Subrata Deb. "SGLT2 Inhibitors as Potential Anticancer Agents." Biomedicines 11, no. 7 (2023): 1867. http://dx.doi.org/10.3390/biomedicines11071867.

Full text
Abstract:
Sodium-glucose cotransporter 2 (SGLT2) serves as a critical glucose transporter that has been reported to be overexpressed in cancer models, followed by increased glucose uptake in both mice and humans. Inhibition of its expression can robustly thwart tumor development in vitro and in vivo. SGLT2 inhibitors are a comparatively new class of antidiabetic drugs that have demonstrated anticancer effects in several malignancies, including breast, liver, pancreatic, thyroid, prostate, and lung cancers. This review aims to assess the extent of SGLT involvement in different cancer cell lines and discu
APA, Harvard, Vancouver, ISO, and other styles
6

Wang, Lujing, Min Liu, Fei Yin, et al. "Trilobatin, a Novel SGLT1/2 Inhibitor, Selectively Induces the Proliferation of Human Hepatoblastoma Cells." Molecules 24, no. 18 (2019): 3390. http://dx.doi.org/10.3390/molecules24183390.

Full text
Abstract:
Studies have indicated that Na+-d-glucose co-transporter (SGLT) inhibitors had anti-proliferative activity by attenuating the uptake of glucose in several tumor cell lines. In this study, the molecular docking showed that, trilobatin, one of the dihydrochalcones from leaves of Lithocarpus polystachyus Rehd., might be a novel inhibitor of SGLT1 and SGLT2, which evidently attenuated the uptake of glucose in vitro and in vivo. To our surprise, we observed that trilobatin did not inhibit, but promoted the proliferation of human hepatoblastoma HepG2 and Huh 7 cells when it was present at high conce
APA, Harvard, Vancouver, ISO, and other styles
7

Kumar, Shubham, Gopal L. Khatik, and Amit Mittal. "Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus." Mini-Reviews in Medicinal Chemistry 20, no. 3 (2020): 170–82. http://dx.doi.org/10.2174/1389557519666191009163519.

Full text
Abstract:
In today’s world, metabolic disorders are much dominant, and among them, diabetes is causing the highest rate of mortality. There is no cure for diabetes, while treatment could be done either by insulin therapy or oral antidiabetic drug. Oral antidiabetic agents target pathogenic factors like receptors, enzymes, genes and proteins involved in diabetes progression. Among them, recently, sodium-glucose co-transporters (SGLTs) have been recognized for their potential to effectively treat Type 2 diabetes mellitus. SGLTs are classified as SGLT-1 and SGLT-2, and among them, SGLT-2 is a major transpo
APA, Harvard, Vancouver, ISO, and other styles
8

Atul, Kshirasagar* Ms. Priyanka Zendekar Dr. Gajanan Sanap. "SGLT Inhibitors As Antidiabetic Agents." International Journal in Pharmaceutical Sciences 1, no. 11 (2023): 168–79. https://doi.org/10.5281/zenodo.10084378.

Full text
Abstract:
One of the most prevalent metabolic diseases that significantly raises the burden of disease on the world health system is diabetes mellitus. Diabetes mellitus (DM) is linked to several illnesses and medical disorders, including atherosclerosis, obesity, hypertension, and cardiovascular diseases. Type 1 diabetes, Type 2 diabetes, and gestational diabetes are the three main forms of diabetes mellitus. Many medication classes, including insulin, biguanides, sulfonylureas, metformin, DPP4 inhibitors, GLP-1 inhibitors, and SGLT2 inhibitors, are used to treat or manage diabetes mellitus. Included i
APA, Harvard, Vancouver, ISO, and other styles
9

Han, Ying, Young-Eun Cho, Ramon Ayon, et al. "SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery." American Journal of Physiology-Lung Cellular and Molecular Physiology 309, no. 9 (2015): L1027—L1036. http://dx.doi.org/10.1152/ajplung.00167.2015.

Full text
Abstract:
Inhibitors of sodium-glucose cotransporter (SGLT)2 are a new class of oral drugs for type 2 diabetic patients that reduce plasma glucose levels by inhibiting renal glucose reabsorption. There is increasing evidence showing the beneficial effect of SGLT2 inhibitors on glucose control; however, less information is available regarding the impact of SGLT2 inhibitors on cardiovascular outcomes. The present study was designed to determine whether SGLT inhibitors regulate vascular relaxation in mouse pulmonary and coronary arteries. Phlorizin (a nonspecific SGLT inhibitor) and canagliflozin (a SGLT2-
APA, Harvard, Vancouver, ISO, and other styles
10

Chonko, Kayla, Giavanna Russo-Alvarez, Diana Isaacs, Lu Wang, and Amanda Soric. "Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate." INNOVATIONS in pharmacy 14, no. 2 (2023): 9. http://dx.doi.org/10.24926/iip.v14i2.5456.

Full text
Abstract:
Sodium glucose cotransporter 2 (SGLT-2) inhibitors have demonstrated benefit in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), including slowing the progression of CKD and lowering the risk of kidney failure and death. Despite this evidence, literature suggests SGLT-2 inhibitors are underutilized in this population. To assess prescribing practices and identify potential variables predictive of SGLT-2 inhibitor prescribing, a non-interventional, retrospective, cross-sectional study was conducted in patients with T2DM and reduced estimated glomerular filtration rat
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "SGLT 2 Inhibitors"

1

Khemais, Sonia. "Induction de la sénescence endothéliale par le high glucose : rôle des transporteurs SGLT1 et SGLT2." Thesis, Strasbourg, 2017. http://www.theses.fr/2017STRAJ081/document.

Full text
Abstract:
La sénescence endothéliale est une étape précoce menant à la dysfonction endothéliale, laquelle favorise la pathogénèse de maladies cardiovasculaires lors du vieillissement physiologique et, de manière prématurée, chez le sujet diabétique. La première étude indique que le stress oxydant favorise l’induction du système angiotensine local menant à la sénescence et la dysfonction endothéliale dans les cellules endothéliales en culture. La deuxième étude indique que l’expression redox-sensible des co-transporteurs sodium-glucose 2 (SGLT2) entraîne via le système angiotensine la sénescence et la dy
APA, Harvard, Vancouver, ISO, and other styles
2

Mittag-Roussou, Vasiliki [Verfasser]. "GLP-1 Agonisten- und SGLT-2 Inhibitoren-Therapie bei Patienten mit nicht alkoholischer Fettlebererkrankung und Diabetes mellitus Typ 2 / Vasiliki Mittag-Roussou." Saarbrücken : Saarländische Universitäts- und Landesbibliothek, 2020. http://d-nb.info/1231792124/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Park, Sin-Hee. "Evaluation du rôle des co-transporteurs sodium-glucose SGLT1 et 2 dans l'induction de la sénescence et de la dysfonction des cellules endothéliales à l'aide d'une approche in vitro et in vivo." Thesis, Strasbourg, 2019. http://www.theses.fr/2019STRAJ041.

Full text
Abstract:
Les inhibiteurs du cotransporteur sodium-glucose SGLT2 ont montré des effets protecteurs cardiovasculaires remarquables avec une réduction du risque de mortalité cardiovasculaire et d’hospitalisation pour insuffisance cardiaque chez des patients atteints de DT2 avec un risque cardiovasculaire élevé, un effet indépendant du contrôle de la glycémie. La possibilité que les inhibiteurs de SGLT1 et 2 protègent le système cardiovasculaire en ciblant la fonction endothéliale protectrice reste incertaine. La première étude in vitro indique que l'angiotensine II et les microparticules circulantes prove
APA, Harvard, Vancouver, ISO, and other styles
4

Andrade, Alda João Araujo. "SGLT-2 inhibitors and nephroprotection: a systematic review and meta-analysis." Master's thesis, 2020. https://hdl.handle.net/10216/128666.

Full text
Abstract:
Introdução: A nefropatia diabética assume-se como uma frequente complicação microvascular da Diabetes Mellitus Tipo 2. Estudos prévios reportaram a diminuição da albuminúria e a preservação da taxa de filtração glomerular como um efeito da classe dos inibidores da SGLT-2. Todavia, alguma incerteza persiste. Desta feita, o objetivo deste trabalho prendeu-se com uma revisão sistemática acerca do uso de inibidores da SGLT-2 e o impacto nos outcomes renais em indivíduos com diabetes mellitus tipo 2. Métodos: Realizamos uma revisão sistemática e meta-análise de estudos randomizados e aleatorizados
APA, Harvard, Vancouver, ISO, and other styles
5

Andrade, Alda João Araujo. "SGLT-2 inhibitors and nephroprotection: a systematic review and meta-analysis." Dissertação, 2020. https://hdl.handle.net/10216/128666.

Full text
Abstract:
Introdução: A nefropatia diabética assume-se como uma frequente complicação microvascular da Diabetes Mellitus Tipo 2. Estudos prévios reportaram a diminuição da albuminúria e a preservação da taxa de filtração glomerular como um efeito da classe dos inibidores da SGLT-2. Todavia, alguma incerteza persiste. Desta feita, o objetivo deste trabalho prendeu-se com uma revisão sistemática acerca do uso de inibidores da SGLT-2 e o impacto nos outcomes renais em indivíduos com diabetes mellitus tipo 2. Métodos: Realizamos uma revisão sistemática e meta-análise de estudos randomizados e aleatorizados
APA, Harvard, Vancouver, ISO, and other styles
6

Figueiredo, Filipa Catarina Oliveira. "RISCO DA UTILIZAÇÃO DOS INIBIDORES DO COTRANSPORTADOR DE SÓDIO-GLUCOSE 2 (SGLT-2) NO IDOSO." Master's thesis, 2019. http://hdl.handle.net/10316/89766.

Full text
Abstract:
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de Medicina<br>Introdução: Os inibidores do cotransportador de sódio-glucose 2 (SGLT-2) são uma classe de antidiabéticos orais usados no controlo glicémico em doentes com diabetes mellitus tipo 2 (DM2). A inibição deste cotransportador resulta num aumento da excreção urinária de glucose com consequente diminuição da sua concentração plasmática.Objectivo: O objectivo desta revisão narrativa é avaliar o risco da utilização destes fármacos na população idosa (≥65anos).Metodologia: Foram consultadas as bases de dados PubMed e
APA, Harvard, Vancouver, ISO, and other styles
7

Crispim, Bernardo Manuel Ribeiro Pereira Simões. "SGLT-2 inhibitors users profile recruited through a pharmacy-based intensive monitoring study: analysis of the pharmacotherapeutic profile, drug-drug interactions, and comparison with the population of the randomized controlled trials." Master's thesis, 2017. http://hdl.handle.net/10451/35979.

Full text
Abstract:
Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2017<br>Diabetes Mellitus (DM) é uma doença crónica que afeta mais de 400 milhões de pessoas globalmente. É caracterizada por hiperglicemia constante devido à incapacidade do organismo produzir insulina, DM tipo 1, ou de utilizar a insulina de forma efetiva, DM tipo 2. Em Portugal, em 2015, a prevalência de DM atingiu 13.3% da população, sendo grande parte dela não diagnosticada. Estima-se que ao DM tipo 2 seja responsável por cerca de 90% do total dos casos, em Portugal e mundialmente,
APA, Harvard, Vancouver, ISO, and other styles
8

Chen, Chiu-Hua, and 陳秋華. "Effects of SGLT-2 inhibitor on mitochondrial function in renal proximal tubular cell." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/94375356743146269174.

Full text
Abstract:
碩士<br>國立中山大學<br>生物科學系研究所<br>104<br>Sodium-glucose cotransporter 2 (SGLT2) inhibitors are newly marketed oral hypoglycemic agents used to treat diabetic patients. They block reabsorption of filtered glucose by inhibiting the primary glucose transporter in the proximal tubular cells (PTC), leading to glycosuria and lowering of serum glucose. A growing body of evidence from diabetic animal studies shows that SGLT2 inhibitors offer kidney benefits in better function, less hyperfiltration, less albuminuria and ameliorating pathology. However, little is known about the underlying mechanisms of these
APA, Harvard, Vancouver, ISO, and other styles
9

Gomes, Irma de Sá Almeida Bragança. "Impact of SGLT2 inhibitors' therapy in Heart Failure." Master's thesis, 2021. http://hdl.handle.net/10316/98602.

Full text
Abstract:
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de Medicina<br>Os inibidores sodium glucose-linked cotransporter 2 (SGLT2) são fármacos hipoglicemiantes orais, cujos mecanismos de ação na Insuficiência cardíaca (IC) ainda não foram totalmente identificados.O objetivo deste estudo foi avaliar se doentes diabéticos com e sem diagnóstico formal de IC reportam melhoria na qualidade de vida relacionada com a saúde (QdVRS) e em biomarcadores cardíacos quando tratados com o inibidor SGLT2 sotaglifozina.Tratou-se de um estudo observacional retrospetivo realizado numa população
APA, Harvard, Vancouver, ISO, and other styles
10

Gomes, Irma de Sá Almeida Bragança. "Impact of SGLT2 inhibitors' therapy in Heart Failure." Master's thesis, 2021. http://hdl.handle.net/10316/98673.

Full text
Abstract:
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de Medicina<br>Os inibidores sodium glucose-linked cotransporter 2 (SGLT2) são fármacos hipoglicemiantes orais, cujos mecanismos de ação na Insuficiência cardíaca (IC) ainda não foram totalmente identificados.O objetivo deste estudo foi avaliar se doentes diabéticos com e sem diagnóstico formal de IC reportam melhoria na qualidade de vida relacionada com a saúde (QdVRS) e em biomarcadores cardíacos quando tratados com o inibidor SGLT2 sotaglifozina.Tratou-se de um estudo observacional retrospetivo realizado numa população
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "SGLT 2 Inhibitors"

1

Nandave, Mukesh, ed. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-7568-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

CHAWLA, Jaggi. Novel Insights on Sglt-2 Inhibitors. Jaypee Brothers Medical Publishers, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Baliga, Ragavendra R., and Deepak L. Bhatt. SGLT-2 Inhibitors, an Issue of Heart Failure Clinics. Elsevier - Health Sciences Division, 2022.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kashyap, Sangeeta. Medical Management of Endocrine Disorders after Bariatric Surgery. Edited by Tomasz Rogula, Philip Schauer, and Tammy Fouse. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190608347.003.0015.

Full text
Abstract:
Endocrine complications after bariatric surgery include persistent hyperglycemia in patients with type 2 diabetes who experience initial success with weight loss. This complication occurs in those with a prolonged duration of diabetes (&gt; 8 years) and is related to poor residual pancreatic beta-cell function. Often, weight regain is associated with recurrent diabetes, and strategies that target both weight loss and glycemic control are required. New diabetes agents, such as the SGLT2 inhibitor drug class, offer advantages to diabetes treatment after bariatric surgery. On the other end of the
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "SGLT 2 Inhibitors"

1

Müller-Wieland, D., J. Brandts, M. Verket, N. Marx, and K. Schütt. "Glycaemic Control in Diabetes." In Prevention and Treatment of Atherosclerosis. Springer International Publishing, 2021. http://dx.doi.org/10.1007/164_2021_537.

Full text
Abstract:
AbstractReduction of glucose is the hallmark of diabetes therapy proven to reduce micro- and macro-vascular risk in patients with type 1 diabetes. However glucose-lowering efficacy trials in type 2 diabetes didn’t show major cardiovascular benefit. Then, a paradigm change in the treatment of patients with type 2 diabetes has emerged due to the introduction of new blood glucose-lowering agents. Cardiovascular endpoint studies have proven HbA1c-independent cardioprotective effects for GLP-1 receptor agonists and SGLT-2 inhibitors. Furthermore, SGLT-2 inhibitors reduce the risk for heart failure
APA, Harvard, Vancouver, ISO, and other styles
2

Lemaire, Sébastien, and Didier Schils. "Development of Efficient Routes to Access C-Glycosides as SGLT-2 Inhibitors for the Treatment of Type 2 Diabetes." In Topics in Heterocyclic Chemistry. Springer International Publishing, 2015. http://dx.doi.org/10.1007/7081_2015_166.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Karaburgu, Sulbiye. "Current Approach of Diabetes Mellitus in Obese Patients." In Current Perspective on Diabetes Mellitus in Clinical Sciences. Nobel Tip Kitabevleri, 2023. http://dx.doi.org/10.69860/nobel.9786053359111.8.

Full text
Abstract:
The current approach to managing diabetes mellitus in obese patients focuses on a comprehensive strategy that addresses both conditions simultaneously. Central to this approach is weight management through lifestyle modifications, including dietary changes and increased physical activity. Caloric restriction, with an emphasis on balanced nutrition that limits simple sugars and unhealthy fats while promoting fiber-rich foods, plays a crucial role. Regular exercise helps improve insulin sensitivity and facilitates weight loss. Pharmacotherapy may include medications that not only lower blood glu
APA, Harvard, Vancouver, ISO, and other styles
4

Cowan, Jenna. "Overview of Type 2 Diabetes." In Essentials of SGLT2 Inhibitors in Diabetes. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-43296-0_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kataria, Ashish, and Christos Argyropoulos. "Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors." In Diabetes and Kidney Disease. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-86020-2_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fisher, Miles. "Guidelines for the Treatment of Type 2 Diabetes Mellitus." In Essentials of SGLT2 Inhibitors in Diabetes. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-43296-0_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Srour, Lara, Jaafar Ismail, Rachel Njeim, and Assaad A. Eid. "Exploring the Evolving Role of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Managing Cardiovascular Injury Induced by Obesity: Spotlight on ROS as a Key Mediator." In Oxidative Stress in Applied Basic Research and Clinical Practice. Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-62131-4_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nandave, Mukesh. "Cardiovascular and Renal Diseases in Type 2 Diabetes." In Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-7568-2_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nandave, Mukesh. "Congestive Heart Failure." In Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-7568-2_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nandave, Mukesh. "Cardiovascular Events, Mortality, and Significant Safety." In Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-7568-2_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "SGLT 2 Inhibitors"

1

Wilcox, P., K. Walter, J. Troost, and E. Belloli. "Safety and Tolerability of SGLT-2 Inhibitors Following Lung Transplantation." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3724.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gronda, Edoardo, Massimo Iacoviello, and Arduino Arduini. "Sodium glucose co-transporter inhibitors put cardiovascular medicine at a crossroads – Cardiorenal interaction and clinical implications." In 7th International Congress of Cardionephrology KARNEF 2025. Punta Niš, 2025. https://doi.org/10.46793/karnef25.215g.

Full text
Abstract:
Heart and kidney have essential homeostatic role in circulation balance to cope with variation of body biology needs, however the two organs physiology is designed to satisfy opposing demands. The heart has to provide with oxygen and nutrition of different organs and apparatus based on intercurrent demand without any predefined schedule. In contrast, the kidneys have to adapt the body’s fluid and electrolyte content to cope with changes in the internal and external environment. The heart and kidney function confront different physiological needs, namely the energy the body requires versus the bo
APA, Harvard, Vancouver, ISO, and other styles
3

Berning, P., and O. Dzaye. "Online searches for SGLT-2 inhibitors and GLP-1 receptor can mirror prescription rates." In Abstracts des Gemeinsamen Kongresses der Deutschen Adipositas-Gesellschaft (DAG) und Deutsche Gesellschaft für Essstörungen (DGESS). Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0043-1771650.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Surducan, Mihai. "Simulated head-to-head comparison of SGLT-2 inhibitors and GLP-1R agonists in type 2 diabetes." In 61st ERA Congress, edited by Rachel Giles. Medicom Medical Publishers, 2024. http://dx.doi.org/10.55788/6f940c73.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hassan, A., H. Salat, A. Ahmed, and T. Khan. "Euglycemic Diabetic Ketoacidosis, SGLT-2 Inhibitors and COVID-19; The Murphy Law of COVID-19." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2448.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zheng, Sean, and Alistair Roddick. "66 Acute coronary syndrome in type 2 diabetes treated using SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors: a comparative network meta-analysis of 127,731 individuals." In British Cardiovascular Society Annual Conference ‘High Performing Teams’, 4–6 June 2018, Manchester, UK. BMJ Publishing Group Ltd and British Cardiovascular Society, 2018. http://dx.doi.org/10.1136/heartjnl-2018-bcs.66.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mishra, S., R. Ali, and S. Abdollahi. "POS1026 ANALYZING RENAL AND CARDIOVASCULAR OUTCOMES IN LUPUS NEPHRITIS: A COMPREHENSIVE COHORT STUDYING THE USE OF SGLT-2 INHIBITORS IN SYSTEMIC LUPUS ERYTHEMATOSUS." In EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria. BMJ Publishing Group Ltd and European League Against Rheumatism, 2024. http://dx.doi.org/10.1136/annrheumdis-2024-eular.6275.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Al-Shamasi, Al-Anood, Meram Elsayed, Nabeel Abdulrahman, Jensa Joseph, and Fatima Mraiche. "The Cardiovascular benefits of Empagliflozin, a Sodium Glucose Cotransporter Inhibitor: Is NHE1 a viable target?" In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0228.

Full text
Abstract:
Empagliflozin (EMPA), an SGLT2 inhibitor (with a low affinity for SGLT1) has attracted much attention due to a recent clinical trial, the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). In this trial, treatment with EMPA over 2.6 years decreased cardiovascular vascular events (14% reduction). Whether EMPA induces cardioprotection, independent of diabetes remains unclear. A previous report has demonstrated that EMPA inhibited NHE1 activity, which led to a reduction in intracellular sodium and calcium. In our study, we examine the cellular interplay b
APA, Harvard, Vancouver, ISO, and other styles
9

LV, WEN-TAO, QIU-MEI ZHANG, and XIANG-WEN MENG. "EFFECT OF SGLT-2 INHIBITOR ON BONE TURNOVER IN OVERWEIGHT AND OBESE PATIENTS WITH TYPE 2 DIABETES." In 2021 International Conference on Education, Humanity and Language, Art. Destech Publications, Inc., 2021. http://dx.doi.org/10.12783/dtssehs/ehla2021/35720.

Full text
Abstract:
To investigate the effect of sodium glucose cotransporter 2 inhibitor (SGLT-2I) on bone turnover markers in overweight and obese patients with type 2 diabetes mellitus. Methods: according to the criteria of selection and exclusion, 42 patients with overweight and obese type 2 diabetes (BMI≥25kg/m2) were selected from October 2019 to May 2020. The patients were randomly divided into experimental group and control group, there were 18 cases in the experimental group and 24 cases in the control group. The experimental group was treated with SGLT-2I, and other oral hypoglycemic agents (or insulin)
APA, Harvard, Vancouver, ISO, and other styles
10

Zaghloul, Nancy, Ahmed Awaisu, Ahmed Mahfouz, Sumaya Al Saadi, and Hazem Elewa. "Trends of use of SGLT2 inhibitors in Qatar." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0108.

Full text
Abstract:
Background: Type 2 diabetes mellitus (T2DM) represents a growing health challenge in Qatar and worldwide. T2DM is associated with a high risk of cardiovascular (CV) morbidity and mortality, and progression of renal disease. Sodium glucose co-transporter 2 inhibitors (SGLT2is) are the most recently approved class of glucose lowering medications (GLMs). To date, there is a limited knowledge about the adoption of SGLT2is by clinicians compared to other oral GLMs in Qatar and Middle East and North Africa (MENA) region. Accordingly, this proposed study aims to explore the trends in SGLT2is use comp
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "SGLT 2 Inhibitors"

1

Watts, Merlin, Stuart McPhail, and David Levy. SGLT-2 Receptor Inhibitors: Pharmacology and Anaesthetic Implications. World Federation of Societies of Anaesthesiologists, 2025. https://doi.org/10.28923/atotw.551.

Full text
Abstract:
This tutorial provides an overview of the pharmacology, indications and potential complications associated with SGLT2 inhibitors. It explains perioperative considerations, focusing on the associated risk of diabetic ketoacidosis. It also compares international guidance and outlines our institution’s approach to managing these agents during surgery.
APA, Harvard, Vancouver, ISO, and other styles
2

Lew, Chong Zhi, and Ting Chi Yeh. Pediatric Extracranial Germ Cell Tumor: Clinical Perspective of Autologous Hematopoietic Cell Transplantation. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.1.0081.

Full text
Abstract:
Review question / Objective: A large number of systematic reviews and meta-analyses (SRs/MAs) involving sodium-glucose cotransporter-2 inhibitors (SGLT-2is) in the treatment of heart failure with preserved ejection fraction (HFpEF) have different outcomes. Condition being studied: The efficacy of SGLT-2is on HFpEF is currently a hot topic. However, the results of SRs/MAs conducted on relevant randomized controlled trials (RCTs) are inconsistent. We aim to conduct an umbrella review of existing SRs/MAs, to comprehensively evaluate study quality, and to incorporate calculated data from RCTs to u
APA, Harvard, Vancouver, ISO, and other styles
3

Husidic, Dejvid. The Effect of SGLT-2 Inhibitors in Non-Diabetic Patients with Diseases Such as Congestive Heart Failure and Chronic Kidney Disease. Iowa State University, 2022. http://dx.doi.org/10.31274/cc-20240624-1425.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Vis, Dalton. SGLT2 Inhibitors and Type 2 Diabetes. Iowa State University, 2022. http://dx.doi.org/10.31274/cc-20240624-1281.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hou, Jingjin, Li Ren, Qingbin Hou, et al. Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.9.0015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ding, Liang-Liang, Mei Qiu, and Yingxi Tang. Comparative efficacy of GLP-1 RAs and SGLT2 inhibitors for prevention of cardiorenal events in type 2 diabetes: a network meta-analysis of cardiovascular outcome trails. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.5.0081.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'SGLT 2 Inhibitors' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography